A 20-year-old male patient with chronic myeloid leukemia (CML), in chronic phase, underwent allogeneic blood stem cell transplantation in August 1996. Engraftment was well documented in the marrow on day 19, but pancytopenia and mild splenomegaly continued. On day +70, the patient developed severe anemia and had one pyrexial episode. He was detected to have malaria (Plasmodium vivax). After chloroquin therapy, the pancytopenia reversed completely. We suggest that malaria should be considered as a possible cause of pancytopenia in the post-transplant period in endemic areas. Keywords: allogeneic blood stem cell transplantation; CML; malaria; pancytopenia Allogeneic bone marrow (allo-BMT) and blood stem cell transplants (allo-BSCT) are being increasingly used in countries where malaria is endemic. Post-transplantation pancytopenia is generally caused by graft-versus-host disease (GVHD), CMV infection, immune mechanisms or graft rejection. We describe a patient with CML who engrafted successfully but continued to have pancytopenia post-transplant which worsened, along with severe anemia on day +70. This was found to be due to Plasmodium vivax and reversed after antimalarials. Absence of such reports in the literature and the fact that confusion can occur because of other better known and more common causes of pancytopenia in this setting prompted us to document this case. Pancytopenia due to malaria has not yet been reported after allogeneic stem cell transplantation.
Allogeneic bone marrow (allo-BMT) and blood stem cell transplants (allo-BSCT) are being increasingly used in countries where malaria is endemic. Post-transplantation pancytopenia is generally caused by graft-versus-host disease (GVHD), CMV infection, immune mechanisms or graft rejection. We describe a patient with CML who engrafted successfully but continued to have pancytopenia post-transplant which worsened, along with severe anemia on day +70. This was found to be due to Plasmodium vivax and reversed after antimalarials. Absence of such reports in the literature and the fact that confusion can occur because of other better known and more common causes of pancytopenia in this setting prompted us to document this case. Pancytopenia due to malaria has not yet been reported after allogeneic stem cell transplantation.
Case report
A 20-year-old male was seen at the Institute Rotary Cancer Hospital (IRCH) of the All India Institute of Medical Sciences (AIIMS) in June 1995 with intermittent fever and /l. Diagnosis of Philadelphia positive (Ph + ) CML in chronic phase was confirmed. Fourteen months after diagnosis while still in chronic phase the patient underwent allogeneic BSCT. Stem cells were harvested from his fully HLAmatched sister using BSCT. A dose of 8 g/kg daily for 4 days was used. For conditioning, busulphan 4 mg/kg for 4 days and cyclophosphamide 60 mg/kg for 2 days were used. Engraftment was confirmed on day +19 and the patient was discharged on day +32. At this time the spleen was still 2 cm palpable, and the patient had mild pancytopenia (see Table 1 ). He continued on cyclosporine. On day +70, he complained of weakness and palpitations.
Examination revealed splenic enlargement of 6 cm and severe anemia. Investigations revealed Hb 3 g/dl, TLC 1.1 × 10 9 /l, and platelets 63 × 10 9 /l. He had a single pyrexial episode with chills. There was no evidence of GVHD or CMV infection. Marrow aspiration showed good cellularity. Peripheral smear examination showed anisopoikilocytosis, polychromasia and schistiocytes. Direct and indirect Coomb's tests were negative. Detailed search of peripheral smear showed schizonts of Plasmodium vivax (Figure 1 ). The patient was prescribed chloroquin base 600 mg on day 1, 300 mg each on days 2 and 3 followed by primaquin 15 mg daily for 2 weeks. His counts started rising on day 3 of antimalarial treatment and by day 10 became normal for the first time after transplant (Hb 10.0 g/dl, TLC 5.2 × 10 9 /l, platelets 168 × 10 9 /l) and the spleen regressed to 1 cm. Table 1 summarizes hematological and liver functions of the patient from the day of transplant up to last follow-up. The transient hepatic dysfunction was attributed to acute GVHD which resolved with treatment. The patient is alive and well 350 days post-transplant.
Discussion
Malaria is the world's most common parasitic infection, and more than 40% of the world's population lives in endemic areas. 1 About 110 million cases are reported each year from over 100 countries and about 1 million people die of malaria each year. 2 It is the falciparum type which is more often associated with serious hematological and metabolic complications. 3 We have found only three case reports of malaria infection following sibling allogeneic bone marrow transplants. [4] [5] [6] There was no reference to pancytopenia caused by malaria in these patients. Although malaria can be acquired from the donor or during blood component therapy post-transplant, in our patient it is more likely that he had infection before transplant and this was not detected. He gave a history of malaria 4-5 years before and his counts continued to be low and splenomegaly persisted post-transplant. These abnormalities corrected fully only after anti-malarial therapy. The diagnosis of malaria was not easy as there was only one episode of fever. It is well known that P. vivax is characterized by exoerythrocytic schizogony in the liver which makes eradication difficult. The dormant hypnozite forms can cause late relapse up to 12 months following initial exposure. Prompt diagnosis depends on a high index of clinical suspicion in endemic areas.
Pancytopenia due to vivax infection is extremely uncommon. An extensive literature search has revealed only one case report of P. vivax infection causing pancytopenia.
